{"id":1885,"date":"2025-01-30T13:47:49","date_gmt":"2025-01-30T13:47:49","guid":{"rendered":"https:\/\/www.nordicbioscience.com\/?page_id=1885"},"modified":"2025-09-02T08:59:35","modified_gmt":"2025-09-02T08:59:35","slug":"board-of-directors","status":"publish","type":"page","link":"https:\/\/www.nordicbioscience.com\/about\/board-of-directors\/","title":{"rendered":"Board of Directors"},"content":{"rendered":"
\n
\n
\n

Board of Directors<\/h1>\n

At Nordic Bioscience, the Board of Directors consists of seasoned and recognized industry veterans. The board ensures the company\u2019s prosperity by collectively directing the company\u2019s affairs, while meeting the appropriate interests of its shareholders and relevant stakeholders.<\/p>\n <\/article>\n <\/div>\n<\/section>\n\n\n\n\n

\n \n
\n
\n
\n
\n

Board of Directors<\/h2>\n \n <\/div>\n
\n <\/div>\n \n <\/div>\n <\/article>\n <\/div>\n <\/section>\n\n\n
\n \n
\n
\n
\n
\n

Chair<\/h2>\n

H\u00e5kan Bj\u00f6rklund<\/h3>\n \n\n <\/div>\n
\n

Dr. H\u00e5kan Bj\u00f6rklund holds a Ph.D. in Neuroscience from Karolinska Institutet and brings extensive experience in the life sciences sector. In addition to serving as Chairman of the Board at Nordic Bioscience, he is also the Chairman at BioPhorum, Asker Healthcare Group AB, Bohus BioTech AB, and Intervacc AB. He is currently a partner at Tellacq AB, a private investment firm.<\/p>\n

Dr. Bj\u00f6rklund has held leadership positions in various life science companies, including CEO of Nycomed, where he led the company’s growth into a global entity before its acquisition by Takeda in 2011. He has also served on the boards of Swedish Orphan Biovitrum AB, QIAGEN, and Lundbeck, among others.<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Vice-chairman<\/h2>\n

Steffen Kragh<\/h3>\n \n\n <\/div>\n
\n

Steffen Kragh holds a Cand.merc and an MBA. Since 2001, he has served as Chief Executive Officer of both the Egmont Foundation and Egmont International Holding Group. Prior to that, he held executive roles at Egmont subsidiaries and worked in the insurance-and-bank sector with Hafnia Holding A\/S, as well as at brokerage firm Erik M\u00f8llers Efterf\u00f8lgere A\/S.<\/p>\n

He currently chairs the Lundbeck Foundation (including Lundbeckfond Invest A\/S) and various Egmont companies. He is Vice Chairman of Tryg A\/S, Tryg Forsikring A\/S and Nordic Bioscience Holding A\/S, and sits on several Egmont board committees (Remuneration, Nomination, and Audit & Risk in Tryg A\/S, plus the Investment Committee in Lundbeck Foundation).<\/p>\n

Over 23 years he has led an international organization with 6,000 employees in consumer markets where technology, data, subscriptions and user experience are central. He formerly chaired Nykredit and served on its Audit, Risk, Remuneration and Nomination Committees. His expertise encompasses strategy, finance and accounting, capital markets, securities and regulatory affairs critical to financial services and corporate governance, as well as data, technology and ESG.<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Other members<\/h2>\n \n <\/div>\n
\n <\/div>\n \n <\/div>\n <\/article>\n <\/div>\n <\/section>\n\n\n
\n \n
\n
\n
\n
\n

Board Member<\/h2>\n

Kugan Sathiyanandarajah<\/h3>\n \n\n <\/div>\n
\n

Kugan Sathiyanandarajah is Head of KKR’s Health Care Strategic Growth business in Europe. Mr. Sathiyanandarajah is a member of the Health Care industry team, and was based in KKR\u2019s Menlo Park office from 2019 to 2020.<\/p>\n

He has played a significant role in a number of KKR\u2019s investments across growth equity and private equity in both Europe and the U.S., including Gamma Biosciences, Argenta, Nordic Bioscience, Biosynth Carbosynth, Alliance Pharma, LGC Group, Walgreens Boots Alliance, Alvogen and Galenica<\/p>\n

He currently serves on the board of directors of Gamma Biosciences, Argenta, Nordic Bioscience, Biosynth Carbosynth and EchoNous. Prior to joining KKR, he was with Goldman Sachs, where he was a member of the UK mergers and acquisitions team. Mr. Sathiyanandarajah earned an M.A. (First Class Hons) in Physical Natural Sciences (Chemistry) from the University of Cambridge.<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Board Member<\/h2>\n

Claus Christiansen, MD, PhD<\/h3>\n \n\n <\/div>\n
\n

Claus Christiansen is the founder of Nordic Bioscience and the Danish Research Foundation. He earned his medical degree in 1971 from University of Copenhagen \u2013 the same year that he published his first peer-reviewed paper.<\/p>\n

His work has changed the field of osteoporosis and he has been instrumental in creating a scientific cross-disciplinary environment for PhDs with an interest in the life science industry. His research is published in high-ranking journals.<\/p>\n

H-factor: 137, as of June 2025.<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Board Member<\/h2>\n

Henrik B. Sanders<\/h3>\n \n\n <\/div>\n
\n

Henrik Bernt Sanders serves as Board member of Nordic Bioscience. He is attorney-at-law from the University of Copenhagen \u2013 Master of Law. Henrik is an equity partner in the Danish law firm Mazanti-Andersen Kors\u00f8 Jensen, advising primarily on mergers and acquisitions. Henrik serves as Chairman of the Board at Mazanti-Andersen Kors\u00f8 Jensen. In addition, Henrik is appointed a permanent administrator by the Danish Maritime and Commercial High Court since 2008.<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

Management<\/h2>\n \n <\/div>\n
\n <\/div>\n \n <\/div>\n <\/article>\n <\/div>\n <\/section>\n\n\n
\n \n
\n
\n
\n
\n

CEO and Head of R&D<\/h2>\n

Morten Karsdal, PhD, mMBA, Prof.<\/h3>\n \n\n <\/div>\n
\n

Prof. Dr. Karsdal joined Nordic Bioscience in 2001 and rose to become CEO in 2010. Karsdal is a visionary leader, renowned for his solid expertise and dedication to biomarker development, the extracellular matrix and disease biology. Prof. Dr. Karsdal has published more than 750 peer-reviewed articles and has presented at numerous global scientific conferences. Additionally, Prof. Dr. Karsdal oversees multiple larger partnerships, as well as 200+ Copenhagen-based staff.<\/p>\n

H-factor: 101, as of June 2025.<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n
\n \n
\n
\n
\n
\n

CFO<\/h2>\n

Thomas Nielsen<\/h3>\n \n\n <\/div>\n
\n

Copenhagen Business School \u2013 M.Sc., Business Economics. Thomas Nielsen joined Nordic Bioscience as CFO in January 2007 after being responsible for the external financial audit of the company since 2003.<\/p>\n

Thomas oversees the Nordic Bioscience administration, including financial, legal, IT and corporate matters.<\/p>\n <\/div>\n <\/div>\n <\/article>\n

\n \"\"\n <\/figure> \n <\/div>\n<\/section>\n\n\n\n
<\/div>\n\n\n
\n \n
\n
\n
\n
\n

Get in touch<\/h2>\n \n\n <\/div>\n
\n
\n
\n Are you interested in exploring collaboration possibilities?\u2028Enter your information in the form and a representative will contact you shortly. <\/div>\n
\n +45 4452 5252<\/a>\n Contact us via email!<\/a>\n <\/div>\n <\/div>\n \n
\n

<\/p>

    <\/ul><\/div>\n
    \n
    \n<\/fieldset>\n
    \n